UroGen inks TumoCure option, up to $7M IntraGel stake

UroGen Pharma Ltd. (URGN) reported that its wholly owned subsidiary, UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. on August 18, 2026.

Rhea-AI Filing Summary

UroGen Pharma Ltd. (URGN) reported that its wholly owned subsidiary, UroGen Pharma, Inc., entered into an Option and Research License Agreement with IntraGel Therapeutics, Ltd. on August 18, 2026. UroGen obtained an exclusive option to secure an exclusive, worldwide license to IntraGel’s TumoCure product formulated with IntraGel’s proprietary SRGel platform for treating advanced head and neck cancer, options for additional SRGel-based products designated by UroGen, and a non-exclusive license to research and evaluate the SRGel platform.

In a related transaction, UroGen Pharma Ltd. agreed, under a Securities Purchase Agreement with IntraGel, to invest up to $7,000,000 in IntraGel’s equity securities, aligning its financial commitment with the collaboration’s development and evaluation activities.

Filing Explained

The commercial licenses remain optional, and no current investment amount or resulting dilution is disclosed.

On August 18, 2026, UroGen disclosed agreements giving its subsidiary options to obtain licenses and providing for an investment of up to $7,000,000; the filing does not report that the options were exercised or that an investment amount was paid.

The exclusive commercial rights are options to obtain licenses, while the disclosed research right is non-exclusive; no exercise of the commercial options is reported.

The investment is stated as up to $7,000,000, so the filing establishes a ceiling rather than a disclosed amount currently invested. It does not provide consideration paid, use of proceeds, conversion terms, or dilution information, leaving the investment’s present cash and ownership effect unquantified.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Key Figures

Maximum equity investment in IntraGel: $7,000,000 Par value of Ordinary Shares: NIS 0.01 per share Commission File Number: 001-38079

3 metrics

Maximum equity investment in IntraGel $7,000,000 Amount UroGen Pharma Ltd. agreed to invest in IntraGel’s equity securities under the Securities Purchase Agreement

Par value of Ordinary Shares NIS 0.01 per share Par value of UroGen Pharma Ltd.’s Ordinary Shares listed on The Nasdaq Stock Market LLC

Commission File Number 001-38079 UroGen Pharma Ltd.’s Commission File Number under the Securities Exchange Act of 1934

Key Terms

Option and Research License Agreement, SRGel platform, TumoCure, biodegradable hydrogel sustained-release delivery platform

4 terms

Option and Research License Agreement regulatory

"entered into an Option and Research License Agreement (the “Option Agreement”)"

SRGel platform medical

"IntraGel’s proprietary, biodegradable hydrogel sustained-release delivery platform (collectively, “SRGel platform”)"

TumoCure medical

"IntraGel’s TumoCure product formulated with IntraGel’s proprietary, biodegradable hydrogel"

biodegradable hydrogel sustained-release delivery platform medical

"IntraGel’s proprietary, biodegradable hydrogel sustained-release delivery platform"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did UroGen Pharma Ltd. (URGN) enter into with IntraGel Therapeutics?

UroGen Pharma Ltd. entered into an Option and Research License Agreement with IntraGel Therapeutics on August 18, 2026. The deal grants UroGen an exclusive option for a worldwide license to IntraGel’s TumoCure product and related SRGel-based products, plus a non-exclusive research license.

How much is UroGen Pharma Ltd. (URGN) investing in IntraGel Therapeutics?

UroGen Pharma Ltd. agreed to invest up to $7,000,000 in IntraGel’s equity securities. This investment is made under a Securities Purchase Agreement executed alongside the option and research license, linking funding to the collaboration’s development efforts.

What rights does UroGen Pharma Ltd. (URGN) receive for the TumoCure product?

UroGen receives an exclusive option to obtain an exclusive, worldwide license to develop, commercialize, and exploit IntraGel’s TumoCure product using the SRGel platform for advanced head and neck cancer. The option structure means full license rights would follow if exercised.

Does UroGen Pharma Ltd. (URGN) obtain rights to other SRGel-based products beyond TumoCure?

Yes. UroGen receives options for additional exclusive, worldwide licenses on products that combine IntraGel’s SRGel platform with compounds designated by UroGen. This allows potential expansion of the collaboration to multiple SRGel-based therapeutics.

What research rights to the SRGel platform does UroGen Pharma Ltd. (URGN) obtain?

UroGen obtains a non-exclusive license to research and evaluate IntraGel’s SRGel platform. This permits UroGen to study the biodegradable hydrogel sustained-release delivery technology in connection with current and potential future product candidates.

When were the agreements between UroGen Pharma Ltd. (URGN) and IntraGel executed?

Both the Option and Research License Agreement and the Securities Purchase Agreement were executed on August 18, 2026. These agreements collectively govern UroGen’s option rights, research access, and investment in IntraGel’s equity securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/20/2026 - 07:04 AM EDT Learn about SEC filing dates

false 0001668243 0001668243 2026-08-18 2026-08-18

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2026

UROGEN PHARMA LTD.

(Exact name of registrant as specified in its charter)

Israel	001-38079	98-1460746
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

400 Alexander Park Drive, 4th Floor Princeton, New Jersey		08540
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +1 (646) 768-9780

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, par value NIS 0.01 per share		URGN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01         Other Events.

On August 18, 2026, UroGen Pharma Ltd. (“the Company”), through its wholly owned subsidiary UroGen Pharma, Inc. (“UroGen U.S.”), entered into an Option and Research License Agreement (the “Option Agreement”) with IntraGel Therapeutics, Ltd. (“IntraGel”), a company organized under the laws of Israel. Pursuant to the Option Agreement, UroGen U.S. obtained from IntraGel (i) an exclusive option to obtain an exclusive, worldwide license under certain intellectual property rights of IntraGel to develop, commercialize and exploit IntraGel’s TumoCure product formulated with IntraGel’s proprietary, biodegradable hydrogel sustained-release delivery platform (collectively, “SRGel platform”) for the treatment of advanced head and neck cancer, (ii) options to obtain exclusive, worldwide licenses under certain intellectual property rights of IntraGel to develop and commercialize additional products combining IntraGel’s SRGel platform with compounds to be designated by UroGen U.S. and (iii) a non-exclusive license to research and evaluate IntraGel's SRGel platform.

In connection with the Option Agreement, on August 18, 2026, the Company entered into a Securities Purchase Agreement with IntraGel, pursuant to which the Company has agreed to invest up to $7,000,000 in the equity securities of IntraGel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 20, 2026	UROGEN PHARMA LTD.
	By:	/s/ Chris Degnan
		Chris Degnan
		Chief Financial Officer

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.5 KB
• EX-101 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE 11.2 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 15.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.3 KB